Alyq Tablet, Film Coated
Product Images NDC 0480-9277

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alyq (NDC 0480-9277). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Alyq Tadalafil Tablets A216932 1)

Chemical structure diagram of the active ingredient Tadalafil, showing its molecular framework with rings and functional groups characteristic of this compound.*

FDA Label Image

Figure 1 (Alyq Tadalafil Tablets A216932 2)

A forest plot chart comparing mean differences in blood pressure measurements between tadalafil and placebo across various coadministered drugs. The chart details changes in systolic and diastolic blood pressure under different conditions such as standing, supine, and ambulatory, with confidence intervals illustrating the variability of results. Drugs coadministered include alcohol, alfuzosin, amlodipine, angiotensin II receptor blockers, doxazosin, tamsulosin, bendroflumethiazide, enalapril, and metoprolol.*

FDA Label Image

Figure 2 (Alyq Tadalafil Tablets A216932 3)

A forest plot illustrating the fold change and 90% confidence intervals of pharmacokinetic parameters (AUC and Cmax) when ALYQ (Tadalafil) is coadministered with various drugs, including CYP3A inhibitors (Ritonavir, Ketoconazole), CYP3A inducers (Rifampin, Bosentan), antacids, and H2 antagonists. The horizontal axis shows change relative to Tadalafil alone, with dosage adjustment or avoidance recommendations listed for each coadministered drug.*

FDA Label Image

Figure 3 (Alyq Tadalafil Tablets A216932 4)

A forest plot depicting fold change with 90% confidence intervals for various coadministered drugs compared to their administration alone. The chart includes CYP1A2, CYP2C9, CYP3A substrates, P-glycoprotein substrates, oral contraceptives, and NSAIDs, showing no dose adjustment recommendations for any listed drugs.*

FDA Label Image

Figure 4 (Alyq Tadalafil Tablets A216932 5)

A line graph comparing the mean change from baseline (in meters) over 16 weeks for placebo versus Tadalafil 40 mg. The x-axis represents weeks (0, 4, 8, 12, 16) and the y-axis shows mean change from baseline. Data points include error bars and significance levels are indicated for Tadalafil versus placebo at weeks 4, 8, and 16.*

FDA Label Image

Figure 5 (Alyq Tadalafil Tablets A216932 6)

A forest plot displaying the placebo-adjusted mean change in 6-minute walk distance (meters) with 95% confidence intervals for Tadalafil 40 mg compared to placebo. The plot breaks down results by subject subsets including Bosentan use, PAH etiology, baseline walk distance, gender, age, and WHO functional class, showing number of subjects and mean changes.*

FDA Label Image

Figure 6 (Alyq Tadalafil Tablets A216932 7)

A Kaplan-Meier plot showing percentage without clinical worsening over time in days for three groups: Tadalafil 40 mg, Tadalafil 20 mg, and Placebo. The y-axis represents the percentage without clinical worsening, ranging from 0 to 100%, and the x-axis shows time to clinical worsening in days, from 0 to 150.*

FDA Label Image

Label, 20mg, 60s (Alyq Tadalafil Tablets A216932 8)

ALYQ 20 mg film-coated tablets label by Teva Pharmaceuticals, Inc. The label shows the proprietary and generic name (Tadalafil) with strength 20 mg. It includes dosage instructions, storage conditions, a barcode, and packaging details for 60 tablets, prescription use only. The label also mentions manufacturing details and a revision date.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.